Clarity Pharmaceuticals Ltd
ASX:CU6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Arabian Drilling Co
SAU:2381
|
SA |
|
F&M Co Ltd
TSE:4771
|
JP |
Clarity Pharmaceuticals Ltd
Other Current Assets
Clarity Pharmaceuticals Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Other Current Assets
AU$6.4m
|
CAGR 3-Years
126%
|
CAGR 5-Years
118%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Other Current Assets
AU$191.4k
|
CAGR 3-Years
4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Other Current Assets
AU$19.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Other Current Assets
AU$9.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Other Current Assets
AU$1.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
19%
|
CAGR 10-Years
8%
|
|
|
Nyrada Inc
ASX:NYR
|
Other Current Assets
AU$3.2m
|
CAGR 3-Years
149%
|
CAGR 5-Years
240%
|
CAGR 10-Years
N/A
|
|
Clarity Pharmaceuticals Ltd
Glance View
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
See Also
What is Clarity Pharmaceuticals Ltd's Other Current Assets?
Other Current Assets
6.4m
AUD
Based on the financial report for Jun 30, 2025, Clarity Pharmaceuticals Ltd's Other Current Assets amounts to 6.4m AUD.
What is Clarity Pharmaceuticals Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
118%
Over the last year, the Other Current Assets growth was 30%. The average annual Other Current Assets growth rates for Clarity Pharmaceuticals Ltd have been 126% over the past three years , 118% over the past five years .
